Behcet’s Disease Plasma

About Behcet’s Disease Plasma

Behcet’s Disease Plasma for Variable-Vessel Vasculitis Research

Behcet’s Disease Plasma is collected from IRB-consented donors with a clinically confirmed diagnosis of Behcet’s disease and processed within one day of collection to preserve cytokines, proteins and metabolites. Plasma is an acellular matrix, so these samples are intended for analyte-level work such as inflammatory mediator profiling, proteomics and metabolomics.

Immune Mechanisms in Behcet’s Disease

Behcet’s disease is a chronic, relapsing variable-vessel vasculitis that can involve arteries and veins of any calibre. Its classification is genuinely debated: the disease is best described as immune-mediated and autoinflammatory-leaning, with prominent innate immune hyperactivity alongside adaptive skewing. No disease-defining autoantibody has been established, so plasma utility rests on inflammatory mediator, proteomic and metabolomic readouts rather than serology.

• Behcet’s disease carries a strong and repeatedly replicated genetic association with HLA-B51; additional susceptibility signals in IL23R/IL12RB2 and ERAP1 tie the disease to the IL-23/IL-17 axis.
• Neutrophil hyperactivity is a hallmark — enhanced chemotaxis, reactive oxygen species generation and infiltration of mucocutaneous and vascular lesions, with corresponding neutrophil-derived mediators measurable in circulation.
• T cell responses are skewed towards Th1 and Th17 phenotypes, and the associated cytokine milieu is accessible to multiplex plasma assays.
• Acute-phase reactants and inflammatory mediators fluctuate markedly between flare and remission, which makes plasma well suited to activity-state and longitudinal designs.
• Thrombosis in Behcet’s disease is driven principally by vascular wall inflammation rather than classical hypercoagulability, making endothelial activation and coagulation-pathway analytes of specific interest in plasma.
• Plasma is the appropriate matrix where coagulation and complement analytes are in scope and where the anticoagulant of collection can be specified in advance.

Donor Stratification Available

• Organ involvement: recurrent oral aphthous ulceration, genital ulceration, ocular/uveitis, vascular, gastrointestinal, or neuro-Behcet’s
• Disease activity: active flare vs clinical remission where documented
• HLA-B51 status where documented
• Treatment status: colchicine, corticosteroid, conventional immunosuppressant, TNF inhibitor, apremilast, or treatment-naive
• Disease duration and age at onset
• Demographics and geographic ancestry, relevant given the disease’s distinctive epidemiology
• Matched healthy controls available

Product Features

• Research Use Only (RUO) human plasma from clinically confirmed Behcet’s disease donors
• Processed within one day of collection to preserve labile analytes
• Anticoagulant and collection tube specified to your protocol where feasible
• Custom aliquot volumes available on request; volumes reported per lot
• IRB-approved protocols and documented informed consent

De-identified Donor Data

• Verified Behcet’s disease diagnosis and diagnostic criteria applied
• Demographics: age, sex assigned at birth, race/ethnicity
• Organ involvement pattern and disease activity where documented
• Donor-reported medications, allergies and comorbidities
• Additional Behcet’s disease-specific metadata available on request

Applications

• Cytokine and inflammatory mediator profiling across flare and remission
• Discovery and validation of disease-activity biomarkers
• Plasma proteomics and metabolomics in variable-vessel vasculitis
• Endothelial activation and coagulation-pathway analyte measurement
• Neutrophil-derived mediator quantification
• IL-23/IL-17 axis analyte studies and target validation support
• Pharmacodynamic and therapeutic response biomarker research
• Control and comparator matrix for vasculitis and autoinflammatory assay panels

Other Behcet’s Disease Specimen Types

• Behcet’s Disease Serum
• Behcet’s Disease Whole Blood
• Behcet’s Disease PBMC

Compliance and Quality Assurance

• IRB-approved and HIPAA-compliant protocols
• Electronic informed consent with 21 CFR Part 11-compliant e-signatures
• Standardised collection and processing SOPs
• Documentation support available for regulatory review

Ordering & Customization

Behcet’s Disease Plasma is available in standard and custom volumes. For pricing, current availability, international orders or documentation requirements, email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. To browse other disease-state options and live stock status across our plasma inventory, visit our human plasma page.